Literature DB >> 26537677

Induction of the Lytic Cycle Sensitizes Epstein-Barr Virus-Infected B Cells to NK Cell Killing That Is Counteracted by Virus-Mediated NK Cell Evasion Mechanisms in the Late Lytic Cycle.

Luke R Williams1, Laura L Quinn1, Martin Rowe1, Jianmin Zuo2.   

Abstract

UNLABELLED: Epstein-Barr Virus (EBV) persists for the lifetime of the infected host despite eliciting strong immune responses. This persistence requires a fine balance between the host immune system and EBV immune evasion. Accumulating evidence suggests an important role for natural killer (NK) cells in this balance. NK cells can kill EBV-infected cells undergoing lytic replication in vitro, and studies in both humans and mice with reconstituted human immune systems have shown that NK cells can limit EBV replication and prevent infectious mononucleosis. We now show that NK cells, via NKG2D and DNAM-1 interactions, recognize and kill EBV-infected cells undergoing lytic replication and that expression of a single EBV lytic gene, BZLF1, is sufficient to trigger sensitization to NK cell killing. We also present evidence suggesting the possibility of the existence of an as-yet-unidentified DNAM-1 ligand which may be particularly important for killing lytically infected normal B cells. Furthermore, while cells entering the lytic cycle become sensitized to NK cell killing, we observed that cells in the late lytic cycle are highly resistant. We identified expression of the vBcl-2 protein, BHRF1, as one effective mechanism by which EBV mediates this protection. Thus, contrary to the view expressed in some reports, EBV has evolved the ability to evade NK cell responses. IMPORTANCE: This report extends our understanding of the interaction between EBV and host innate responses. It provides the first evidence that the susceptibility to NK cell lysis of EBV-infected B cells undergoing lytic replication is dependent upon the phase of the lytic cycle. Induction of the lytic cycle is associated with acquired sensitization to NK cell killing, while progress through the late lytic cycle is associated with acquired resistance to killing. We provide mechanistic explanations for this novel observation, indicating important roles for the BZLF1 immediate early transactivator, the BHRF1 vBcl-2 homologue, and a novel ligand for the DNAM-1 NK cell receptor.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26537677      PMCID: PMC4702672          DOI: 10.1128/JVI.01932-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  Induction of Epstein-Barr virus-associated nuclear antigen during in vitro transformation of human lymphoid cells.

Authors:  W Leibold; T D Flanagan; J Menezes; G Klein
Journal:  J Natl Cancer Inst       Date:  1975-01       Impact factor: 13.506

2.  Novel Association of Killer Cell Immunoglobulin-like Receptor Genes with EBV-infectious Diseases in Children.

Authors:  Li Huo; Ming Yan Jiang; Qiang Li; Yi Ping Zhu
Journal:  Biomed Environ Sci       Date:  2015-04       Impact factor: 3.118

3.  Characterization of a major protein with a molecular weight of 160,000 associated with the viral capsid of Epstein-Barr virus.

Authors:  B Vroman; J Luka; M Rodriguez; G R Pearson
Journal:  J Virol       Date:  1985-01       Impact factor: 5.103

4.  Characteristics of a human cell line transformed by DNA from human adenovirus type 5.

Authors:  F L Graham; J Smiley; W C Russell; R Nairn
Journal:  J Gen Virol       Date:  1977-07       Impact factor: 3.891

5.  Executioner caspase-3, -6, and -7 perform distinct, non-redundant roles during the demolition phase of apoptosis.

Authors:  E A Slee; C Adrain; S J Martin
Journal:  J Biol Chem       Date:  2000-10-31       Impact factor: 5.157

6.  Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells.

Authors:  Daphna Nachmani; Noam Stern-Ginossar; Ronit Sarid; Ofer Mandelboim
Journal:  Cell Host Microbe       Date:  2009-04-23       Impact factor: 21.023

7.  Establishment in continuous culture of a new type of lymphocyte from a "Burkitt like" malignant lymphoma (line D.G.-75).

Authors:  H Ben-Bassat; N Goldblum; S Mitrani; T Goldblum; J M Yoffey; M M Cohen; Z Bentwich; B Ramot; E Klein; G Klein
Journal:  Int J Cancer       Date:  1977-01       Impact factor: 7.396

8.  Latent Membrane Protein LMP2A Impairs Recognition of EBV-Infected Cells by CD8+ T Cells.

Authors:  Chiara Rancan; Leah Schirrmann; Corinna Hüls; Reinhard Zeidler; Andreas Moosmann
Journal:  PLoS Pathog       Date:  2015-06-11       Impact factor: 6.823

9.  Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer.

Authors:  Mirjam H M Heemskerk; Manja Hoogeboom; Renate Hagedoorn; Michel G D Kester; Roel Willemze; J H Frederik Falkenburg
Journal:  J Exp Med       Date:  2004-03-29       Impact factor: 14.307

10.  Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule.

Authors:  Cristina Bottino; Roberta Castriconi; Daniela Pende; Paola Rivera; Marina Nanni; Barbara Carnemolla; Claudia Cantoni; Jessica Grassi; Stefania Marcenaro; Nicolas Reymond; Massimo Vitale; Lorenzo Moretta; Marc Lopez; Alessandro Moretta
Journal:  J Exp Med       Date:  2003-08-11       Impact factor: 14.307

View more
  13 in total

Review 1.  The Immune Response to Epstein Barr Virus and Implications for Posttransplant Lymphoproliferative Disorder.

Authors:  Olivia M Martinez; Sheri M Krams
Journal:  Transplantation       Date:  2017-09       Impact factor: 4.939

2.  Generation of highly proliferative, rejuvenated cytotoxic T cell clones through pluripotency reprogramming for adoptive immunotherapy.

Authors:  Yohei Kawai; Ai Kawana-Tachikawa; Shuichi Kitayama; Tatsuki Ueda; Shoji Miki; Akira Watanabe; Shin Kaneko
Journal:  Mol Ther       Date:  2021-05-21       Impact factor: 12.910

Review 3.  EBV and Apoptosis: The Viral Master Regulator of Cell Fate?

Authors:  Leah Fitzsimmons; Gemma L Kelly
Journal:  Viruses       Date:  2017-11-13       Impact factor: 5.048

4.  Two alternate strategies for innate immunity to Epstein-Barr virus: One using NK cells and the other NK cells and γδ T cells.

Authors:  Zakia Djaoud; Lisbeth A Guethlein; Amir Horowitz; Tarik Azzi; Neda Nemat-Gorgani; Daniel Olive; David Nadal; Paul J Norman; Christian Münz; Peter Parham
Journal:  J Exp Med       Date:  2017-05-03       Impact factor: 14.307

5.  Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models.

Authors:  Eda K Holl; Michael C Brown; David Boczkowski; Megan A McNamara; Daniel J George; Darell D Bigner; Matthias Gromeier; Smita K Nair
Journal:  Oncotarget       Date:  2016-11-29

Review 6.  Human NK Cells and Herpesviruses: Mechanisms of Recognition, Response and Adaptation.

Authors:  Mariella Della Chiesa; Andrea De Maria; Letizia Muccio; Federica Bozzano; Simona Sivori; Lorenzo Moretta
Journal:  Front Microbiol       Date:  2019-10-04       Impact factor: 5.640

Review 7.  Natural Killer Cell Responses during Human γ-Herpesvirus Infections.

Authors:  Christian Münz
Journal:  Vaccines (Basel)       Date:  2021-06-15

Review 8.  Viral Evasion of Natural Killer Cell Activation.

Authors:  Yi Ma; Xiaojuan Li; Ersheng Kuang
Journal:  Viruses       Date:  2016-04-12       Impact factor: 5.048

Review 9.  NK Cell Influence on the Outcome of Primary Epstein-Barr Virus Infection.

Authors:  Obinna Chijioke; Vanessa Landtwing; Christian Münz
Journal:  Front Immunol       Date:  2016-08-29       Impact factor: 7.561

10.  A Temporal Proteomic Map of Epstein-Barr Virus Lytic Replication in B Cells.

Authors:  Ina Ersing; Luis Nobre; Liang Wei Wang; Lior Soday; Yijie Ma; Joao A Paulo; Yohei Narita; Camille W Ashbaugh; Chang Jiang; Nicholas E Grayson; Elliott Kieff; Steven P Gygi; Michael P Weekes; Benjamin E Gewurz
Journal:  Cell Rep       Date:  2017-05-16       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.